Affiliations 

  • 1 Hussein Z, MRCP. Department of Medicine, Hospital Putrajaya, Putrajaya, Presint 7, 62250 Malaysia
  • 2 Department of Radiology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
  • 3 Colman P G, FRACP. Department of Diabetes and Endocrinology, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Med J Malaysia, 2005 Jun;60(2):232-6.
PMID: 16114168

Abstract

Thyrotoxicosis due to Graves disease is a relatively common endocrine disorder. The occurrence of a prolactinoma with co-secretion of growth hormone (GH) is on the other hand, rare. We report the rare co-existence of Graves' disease in a patient with macroprolactinoma and GH hypersecretion and describe the successful response to medical therapy with dopamine agonist and antithyroid therapy. We hypothesize that hyperprolactinaemia played a role in promoting autoimmune thyroid disease in our patient and that treatment of hyperprolactinaemia may have been important in suppressing autoimmune disease activity in Graves' disease. This case also reflects on the close and complex interactions between thyroid hormones, prolactin (PRL), GH and testosterone (T).

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.